A biotechnology company, based in France, developing protein-based therapeutics for immunologicals with a focus on addressing unmet medical need.
Nasdaq: Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
MELBOURNE, Australia and SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
Seeking Alpha: Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026
Voyager Therapeutics' anti-tau monoclonal antibody VY7523 demonstrated an excellent safety and PK profile in phase 1 SAD. Read why VYGR stock is a Strong Buy.
Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026
Insider Monkey on MSN: AgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447
AgomAb Therapeutics NV (NASDAQ:AGMB) is one of the 7 Best Strong Buy European Stocks to Invest In. On , AgomAb Therapeutics NV (NASDAQ:AGMB) announced that the U.S. Patent and Trademark ...
Viking Therapeutics has reached a significant clinical milestone, completing patient enrollment for its second Phase 3 trial. With the VANQUISH-2 study now full ...
Rutland Herald: Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers
Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage therapeutics company advancing novel neuropsychiatric medicines with a proven strategy and team, today announced positive topline ...